Supernus to receive $30M in non-dilutive royalty deal Supernus Pharmaceuticals announced the execution of a royalty acquisition agreement with HealthCare Royalty Partners. Per the Agreement, HC Royalty will make a $30M cash payment to Supernus in consideration for acquiring from Supernus certain royalty and milestone rights related to the commercialization of Orenitram Extended-Release Tablets by Supernus' partner United Therapeutics Corporation. Supernus will retain full ownership of the Royalty Rights after a certain threshold has been reached per the terms of the Agreement.
Supernus raises FY14 revenue view to $115M-$118M from $105M FY14 consensus $104.44M. The company is reducing its cash burn guidance for the year from $5M-10M to approximately $5M, and raising its guidance for year end cash and marketable securities to approximately $85M. The company anticipates achieving cash flow break even by year end and being profitable in 2015.